Reliable XAI Explanations in Sudden Cardiac Death Prediction for Chagas Cardiomyopathy

Sudden cardiac death (SCD) is unpredictable, and its prediction in Chagas cardiomyopathy (CC) remains a significant challenge, especially in patients not classified as high risk. While AI and machine learning models improve risk stratification, their adoption is hindered by a lack of transparency, as they are often perceived as \textit{black boxes} with unclear decision-making processes. Some approaches apply heuristic explanations without correctness guarantees, leading to mistakes in the decision-making process. To address this, we apply a logic-based explainability method with correctness guarantees to the problem of SCD prediction in CC. This explainability method, applied to an AI classifier with over 95\% accuracy and recall, demonstrated strong predictive performance and 100\% explanation fidelity. When compared to state-of-the-art heuristic methods, it showed superior consistency and robustness. This approach enhances clinical trust, facilitates the integration of AI-driven tools into practice, and promotes large-scale deployment, particularly in endemic regions where it is most needed.

Enhancing Framingham Cardiovascular Risk Score Transparency through Logic-Based XAI

Cardiovascular disease (CVD) remains one of the leading global health challenges, accounting for more than 19 million deaths worldwide. To address this, several tools that aim to predict CVD risk and support clinical decision making have been developed. In particular, the Framingham Risk Score (FRS) is one of the most widely used and recommended worldwide. However, it does not explain why a patient was assigned to a particular risk category nor how it can be reduced. Due to this lack of transparency, we present a logical explainer for the FRS. Based on first-order logic and explainable artificial intelligence (XAI) fundaments, the explainer is capable of identifying a minimal set of patient attributes that are sufficient to explain a given risk classification. Our explainer also produces actionable scenarios that illustrate which modifiable variables would reduce a patient's risk category. We evaluated all possible input combinations of the FRS (over 22,000 samples) and tested them with our explainer, successfully identifying important risk factors and suggesting focused interventions for each case. The results may improve clinician trust and facilitate a wider implementation of CVD risk assessment by converting opaque scores into transparent and prescriptive insights, particularly in areas with restricted access to specialists.